Haleon plc Reports Share Transaction
Ticker: HLNCF · Form: 6-K · Filed: Sep 11, 2025 · CIK: 1900304
Sentiment: neutral
Topics: share-transaction, 6-K, reporting
TL;DR
Haleon bought back its own shares on 9/11/25. #ShareRepurchase
AI Summary
Haleon plc announced on September 11, 2025, that it conducted a transaction involving its own shares. The filing, a Form 6-K, details this transaction as part of its reporting for the month of September 2025. This report is filed under the Securities Exchange Act of 1934.
Why It Matters
This filing indicates corporate activity related to Haleon's own stock, which could signal management's view on the company's valuation or be part of a broader capital allocation strategy.
Risk Assessment
Risk Level: low — The filing is a routine report of a share transaction and does not contain information suggesting significant new risks.
Key Players & Entities
- Haleon plc (company) — Registrant
- 001-41411 (dollar_amount) — Commission File Number
- September 11, 2025 (date) — Date of Transaction
FAQ
What type of transaction did Haleon plc conduct in its own shares?
Haleon plc conducted a transaction in its own shares, as detailed in the filing dated September 11, 2025.
What is the purpose of this Form 6-K filing?
This Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of September 2025.
What is Haleon plc's commission file number?
Haleon plc's commission file number is 001-41411.
When was the transaction in own shares reported?
The transaction in own shares was reported on September 11, 2025.
What is Haleon plc's principal executive office address?
Haleon plc's principal executive office is located at Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY.
Filing Stats: 572 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-09-11 08:55:17
Filing Documents
- a8599y.htm (6-K) — 34KB
- a8599y000.jpg (GRAPHIC) — 3KB
- 0001654954-25-010641.txt ( ) — 39KB
From the Filing
IN OWN SHARES a8599y   UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of September 2025   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description 99.1 11 September 2025 - “Transaction in Own Shares”     99.1       Haleon plc:   Transaction in own shares   11 September 2025:   Haleon plc (the "Company" or "Haleon") today announces   the purchase of 172,878 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation   under the second tranche of its share buyback programme announced on 31 July 2025.     London Stock Exchange CBOE (UK)/BXE CBOE (UK)/CXE Date of purchase: 10 September 2025 10 September 2025 10 September 2025 Number of Shares purchased: 172,878 - - Highest price paid per Share (p): 364.0000 - - Lowest price paid per Share (p): 363.5000 - - Volume weighted average price paid per Share (p): 363.8412 - -   Following the settlement of the above, the Company's registered share capital   is 8,952,651,173 ordinary shares of £0.01 each, of which 1,580,205 are held as treasury shares.   Therefore, the number of ordinary shares with voting rights is 8,951,070,968 and   this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.   In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:   http://www.rns-pdf.londonstockexchange.com/rns/8592Y_1-2025-9-10.pdf   This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.   This announcement and individual trade breakdown will also be available on the Company's website at:   www.haleon.com/investors .   Enquiries     Investors Media   Jo Russell   +44 7787 392441 Zoë   Bird +44 7736 746167 Rakesh Patel      +44 7552 484646 Victoria Durman +44 7894 505730 Email:   investor-relations@haleon.com Email:   corporate.media@haleon.com   About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as  Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu  and  Voltaren  - are built on trusted science, innovation and deep human understanding.   For more information, please visit   www.haleon.com .        SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: September 11, 2025 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary